V

Velocity Clinical Research | Grand Island, NE

Research site

(Unclaimed)

Location

3537 West 13th Street Suite 100, Grand Island, Nebraska, United States of America

Site insights

Top conditions

Top treatments

Erenumab

Rimegepant

Parent organization

This site is a part of Velocity Clinical Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 9 total trials

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.

Enrolling

Epstein-Barr Virus Infection

Biological: Placebo

Biological: mRNA-1195.1

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)

In this open-label Phase 3b, single arm trial, persistence of antibodies and long term safety will be evaluated in up to 375 participants rolled over...

Active, not recruiting

Chikungunya Virus Infection

Biological: VLA1553

Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine (OASIS(EM))

This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years)...

Enrolling

Migraine

Drug: Erenumab Dose 3

Drug: Erenumab Dose 1

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and ado...

Enrolling

Migraine

Drug: Placebo

Drug: Rimegepant